What next for rheumatoid arthritis therapy?

Current Opinion in Pharmacology

Volumn 4, Issue 3, 2004, Pages 276-280

  Blake, Simon M ^a   Swift, Barbara A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 15; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 18; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; NITRIC OXIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; RITUXIMAB; ROSIGLITAZONE; STEROID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HUMAN; IC 50; JOINT DESTRUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; T LYMPHOCYTE; TARGET CELL;

EID: 2342579457     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.04.001     Document Type: Review

References (40)

1. Redlich K. Schett G. Steiner G. Hayer S. Wagner E.F. Smolen J.S. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade Arthritis Rheum 48 2003 3308-3319
2. Feldmann M. Brennan F.M. Foxwell B.M. Maini R.N. The role of TNF alpha and IL-1 in rheumatoid arthritis Curr Dir Autoimmun 3 2001 188-199
3. Keane J. Gershon S. Wise R.P. Mirabile-Levens E. Kasznica J. Schwieterman W.D. Siegel J.N. Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098-1104
4. Wong P.K. Campbell I.K. Egan P.J. Ernst M. Wicks I.P. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover Arthritis Rheum 48 2003 1177-1189
5. Boe A. Baiocchi M. Carbonatto M. Papoian R. Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis Cytokine 11 1999 1057-1064
6. Choy E.H. Isenberg D.A. Garrood T. Farrow S. Ioannou Y. Bird H. Cheung N. Williams B. Hazleman B. Price R. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial Arthritis Rheum 46 2002 3143-3150
7. Liew F.Y. Wei X.Q. McInnes I.B. Role of interleukin 18 in rheumatoid arthritis Ann Rheum Dis 62Suppl 2 2003 ii48-ii50
8. Plater-Zyberk C. Joosten L.A. Helsen M.M. Sattonnet-Roche P. Siegfried C. Alouani S. van De Loo F.A. Graber P. Aloni S. Cirillo R. et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis J Clin Invest 108 2001 1825-1832
9. Ruchatz H. Leung B.P. Wei X.Q. McInnes I.B. Liew F.Y. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology J Immunol 160 1998 5654-5660
10. McInnes I.B. Gracie J.A. Harnett M. Harnett W. Liew F.Y. New strategies to control inflammatory synovitis: interleukin 15 and beyond Ann Rheum Dis 62Suppl 2 2003 ii51-ii54
11. Nakae S. Nambu A. Sudo K. Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice J Immunol 171 2003 6173-6177
12. Nakae S. Saijo S. Horai R. Sudo K. Mori S. Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist Proc Natl Acad Sci U S A 100 2003 5986-5990
13. Lubberts E. Koenders M.I. Oppers-Walgreen B. van den Bersselaar L. Coenen-de Roo C.J. Joosten L.A. van den Berg W.B. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheum 50 2004 650-659
14. Blake SM, James IE: Receptor Activator of NF-kB Ligand (RANKL). In The Cytokine Handbook. Edited by Thomson AW, Lotze MT. London: Harcourt Press; 2003.
15. Kotake S. Udagawa N. Hakoda M. Mogi M. Yano K. Tsuda E. Takahashi K. Furuya T. Ishiyama S. Kim K.J. et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients Arthritis Rheum 44 2001 1003-1012
16. Kong Y.Y. Feige U. Sarosi I. Bolon B. Tafuri A. Morony S. Capparelli C. Li J. Elliott R. McCabe S. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 1999 304-309
17. Romas E. Sims N.A. Hards D.K. Lindsay M. Quinn J.W. Ryan P.F. Dunstan C.R. Martin T.J. Gillespie M.T. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis Am J Pathol 161 2002 1419-1427
18. Bolon B. Campagnuolo G. Feige U. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis Cell Mol Life Sci 59 2002 1569-1576
19. Campagnuolo G. Bolon B. Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis Arthritis Rheum 46 2002 1926-1936
20. Kumar S. Boehm J. Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases Nat Rev Drug Discov 2 2003 717-726
21. Roshak A.K. Callahan J.F. Blake S.M. Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease Curr Opin Pharmacol 2 2002 316-321
22. Ghosh S. Karin M. Missing pieces in the NF-kappaB puzzle Cell 109Suppl 2002 S81-S96
23. Karin M. Yamamoto Y. Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development Nat Rev Drug Discov 3 2004 17-26
24. Burke J.R. Pattoli M.A. Gregor K.R. Brassil P.J. MacMaster J.F. McIntyre K.W. Yang X. Iotzova V.S. Clarke W. Strnad J. et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice J Biol Chem 278 2003 1450-1456
25. Castro A.C. Dang L.C. Soucy F. Grenier L. Mazdiyasni H. Hottelet M. Parent L. Pien C. Palombella V. Adams J. Novel IKK inhibitors: beta-carbolines Bioorg Med Chem Lett 13 2003 2419-2422
26. Murata T. Shimada M. Sakakibara S. Yoshino T. Kadono H. Masuda T. Shimazaki M. Shintani T. Fuchikami K. Sakai K. et al. Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1 Bioorg Med Chem Lett 13 2003 913-918
27. Roshak A. Marshall L. Carlson K. Podolin P. Bolognese B. Hoffman S. Imburgia C. Li Y.H. Lang X. et al. A small molecule inhibitor of IκB kinase blocks inflammation and protects joint integrity in in vivo models of arthritis Inflamm Res 51Suppl 2 2002 S4
28. McIntyre K.W. Shuster D.J. Gillooly K.M. Dambach D.M. Pattoli M.A. Lu P. Zhou X.D. Qiu Y. Zusi F.C. Burke J.R. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice Arthritis Rheum 48 2003 2652-2659
29. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus Clin Ther 26 2004 177-190
30. Devchand P.R. Keller H. Peters J.M. Vazquez M. Gonzalez F.J. Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control Nature 384 1996 39-43
31. Delerive P. De Bosscher K. Besnard S. Vanden Berghe W. Peters J.M. Gonzalez F.J. Fruchart J.C. Tedgui A. Haegeman G. Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1 J Biol Chem 274 1999 32048-32054
32. Chung S.W. Kang B.Y. Kim S.H. Pak Y.K. Cho D. Trinchieri G. Kim T.S. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B J Biol Chem 275 2000 32681-32687
33. Sabatini M. Bardiot A. Lesur C. Moulharat N. Thomas M. Richard I. Fradin A. Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro Osteoarthritis Cartilage 10 2002 673-679
34. Bordji K. Grillasca J.P. Gouze J.N. Magdalou J. Schohn H. Keller J.M. Bianchi A. Dauca M. Netter P. Terlain B. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes J Biol Chem 275 2000 12243-12250
35. Fahmi H. Di Battista J.A. Pelletier J.P. Mineau F. Ranger P. Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes Arthritis Rheum 44 2001 595-607
36. Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K, Lavigne M, and Fahmi H: Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta. J Biol Chem 2004.
37. Cuzzocrea S. Mazzon E. Dugo L. Patel N.S. Serraino I. Di Paola R. Genovese T. Britti D. De Maio M. Caputi A.P. et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma Arthritis Rheum 48 2003 3544-3556
38. Moreland L.W. Alten R. Van den Bosch F. Appelboom T. Leon M. Emery P. Cohen S. Luggen M. Shergy W. Nuamah I. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 46 2002 1470-1479
39. Edwards J.C. Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology (Oxford) 40 2001 205-211
40. Szechinski J. Filipowicz-Sosnowska A. Close D. Stevens R.M. Felicia-Szczepanski L. Shaw T.M. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomised, placebo controlled trial in patients with rheumatoid arthritis [abstract] Arth Rheum 46Suppl 2002 S197